Market research
XP0.F Xenon Pharmaceuticals Inc
F EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 27.88
- Dividend yield
- Not available
- Beta
- 0.6
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA98420N1050
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 27.88
- Dividend yield
- Not available
- Beta
- 0.6
About
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Research context
Xenon Pharmaceuticals Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the XP0.F discussion.
5 years, 6 months ago
Xenon Pharmaceuticals Inc is currently in a long term uptrend where the price is trading 17.3% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.0.
Xenon Pharmaceuticals Inc's total revenue rose by 54.7% to $5M since the same quarter in the previous year.
Its net income has dropped by 8.3% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 172.8% to $-14M since the same quarter in the previous year.
Based on the above factors, Xenon Pharmaceuticals Inc gets an overall score of 3/5.